Sectors
TRVI
Trevi Therapeutics, Inc.
17.80
1 x 17.50
1 x 19.50
bid
ask
+
0.00
0.00%
undefined @ 04:00 PM
17.80 +0.00 (0.00%)
| Ytd | 42.17% | |
| 1y | 143.17% |
17.52
day range
18.39
6.93
52 week range
20.22
| Open | 17.97 | Prev Close | 17.80 | Low | 17.52 | High | 18.39 | Mkt Cap | 2.53B |
| Vol | 1.27M | Avg Vol | 2.07M | EPS | -0.34 | P/E | -52.35 | Forward P/E | -32.47 |
| Beta | 1.07 | Short Ratio | 4.19 | Inst. Own | 99.93% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-05 | 50-d Avg | 16.91 | 200-d Avg | 13.39 | 1yr Est | 28.18 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-12 | 2026-09 | -0.13 | N/A | N/A | N/A |
| 2026-08-06 | 2026-06 | -0.11 | -0.11 | N/A | -0.49% |
| 2026-05-05 | 2026-03 | -0.07 | -0.09 | -0.02 | -28.57% |
| 2026-03-17 | 2025-12 | -0.1 | -0.06 | 0.04 | 40.00% |
| 2025-11-13 | 2025-09 | -0.1 | -0.08 | 0.02 | 20.00% |
| 2025-08-07 | 2025-06 | -0.1 | -0.09 | 0.01 | 10.00% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-08-07 | Oppenheimer | Upgrade | Outperform | Outperform |
| 2026-08-07 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
| 2026-07-21 | BMO Capital | Upgrade | Outperform | Outperform |
| 2026-07-20 | B. Riley Securities | Upgrade | Buy | Buy |
| 2026-07-20 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-05-20 | Needham | Upgrade | Buy | Buy |
Profile
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2025-04-16 | BASKETT FOREST | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
| 2025-04-16 | BEHBAHANI ALI | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
| 2025-04-16 | CHANG CARMEN | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
| 2025-04-16 | FLORENCE ANTHONY A JR | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
| 2025-04-16 | MAKHZOUMI MOHAMAD | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
| 2024-08-26 | MEEKER DAVID P | Director | 352.49K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | NEA Management Company, LLC | 13.22M | 244.74M | 9.28% |
| 2026-06-29 | Blackrock Inc. | 11.16M | 206.48M | 7.83% |
| 2026-03-30 | Frazier Life Sciences Management, L.P. | 9.94M | 183.98M | 6.98% |
| 2026-03-30 | FMR, LLC | 8.04M | 148.78M | 5.64% |
| 2026-03-30 | Wellington Management Group, LLP | 5.19M | 96.05M | 3.64% |
| 2026-03-30 | Vivo Capital, LLC | 5.09M | 94.30M | 3.58% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.70M | 68.47M | 2.60% |
| 2026-06-29 | iShares Trust-iShares Russell 2000 ETF | 2.77M | 51.22M | 1.94% |
| 2026-03-30 | MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 2.62M | 48.54M | 1.84% |
| 2026-06-29 | Fidelity Select Portfolios-Select Biotechnology Portfolio | 2.37M | 43.96M | 1.67% |
| 2026-05-30 | Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 1.95M | 36.10M | 1.37% |
| 2026-05-30 | AB CAP FUND, INC.-AB Small Cap Growth Portfolio | 1.20M | 22.22M | 0.84% |